From the Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA.
Department of Hematology and Medical Oncology.
Clin Nucl Med. 2023 Jan 1;48(1):e26-e27. doi: 10.1097/RLU.0000000000004385. Epub 2022 Sep 6.
A 41-year-old woman with invasive lobular carcinoma of the breast underwent sequential 68Ga-PSMA-11 PET/CT and 18F-fluciclovine PET/CT as part of an ongoing clinical trial (NCT04750473). 68Ga-PSMA PET/CT showed increased radiotracer uptake in the uterine endometrium and left adnexa. 18F-fluciclovine PET/CT showed increased radiotracer uptake in a leiomyomatous uterus. A clinical 18F-FDG PET/CT demonstrated radiotracer uptake in the endometrium and a circumferential area of uptake in the left adnexa, a pattern more similar to the 68Ga-PSMA uptake pattern. This case highlights the discordance in the uptake pattern of 2 radiotracers approved for prostate cancer imaging but increasingly used in non-prostate malignancies imaging.
一位 41 岁的女性患有浸润性小叶癌，作为正在进行的临床试验（NCT04750473）的一部分，她接受了连续的 68Ga-PSMA-11 PET/CT 和 18F-氟柳氯胺 PET/CT 检查。68Ga-PSMA PET/CT 显示子宫子宫内膜和左侧附件放射性示踪剂摄取增加。18F-氟柳氯胺 PET/CT 显示子宫肌瘤子宫放射性示踪剂摄取增加。临床 18F-FDG PET/CT 显示子宫内膜和左侧附件放射性示踪剂摄取的环状区域，摄取模式更类似于 68Ga-PSMA 摄取模式。本病例突出了两种放射性示踪剂在用于前列腺癌成像但越来越多地用于非前列腺恶性肿瘤成像方面的摄取模式不一致。
